Federal enforcement of the False Claims Act (FCA) against healthcare and pharmaceutical companies—especially based on alleged Anti-Kickback Statute (AKS) violations—continues to change, with the ...
Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a ...
Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...
Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...
4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...
Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...
Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc., an ...
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a pivotal Phase ...
With a modest $7 million up front but an ultimate payout potentially topping $1 billion on the line, Modex Therapeutics Inc.
Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...
Physical function decline is an increasingly recognised concern among individuals with long-term conditions such as Type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback